Chemical genetic discovery of targets and anti-targets for cancer polypharmacology

  title={Chemical genetic discovery of targets and anti-targets for cancer polypharmacology},
  author={Arvin C. Dar and Tirtha Kamal Das and Kevan M. Shokat and Ross L. Cagan},
The complexity of cancer has led to recent interest in polypharmacological approaches for developing kinase-inhibitor drugs; however, optimal kinase-inhibition profiles remain difficult to predict. Using a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug profiling, here we identify that AD57 rescues oncogenic Ret-induced lethality, whereas related Ret inhibitors imparted reduced efficacy and enhanced toxicity. Drosophila genetics and compound… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 17 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 105 extracted citations


Publications referenced by this paper.
Showing 1-10 of 39 references

a randomized, double-blind Phase III trial

  • Wells, S. A. Jr et al. Vandetanib in patients with locally a cancer
  • J. Clin. Oncol. 30, 134–141
  • 2012

A Phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

  • Haura, B E.
  • Clin. Cancer Res
  • 2010

Clinical experience with aurora kinase inhibitors : a review

  • E. B. Haura
  • Oncologist
  • 2009

Similar Papers

Loading similar papers…